Organisation paid for research Program year 2025 Source: CMS Open Payments

Geisinger Health System

Neither a doctor nor a teaching hospital

Research payments

$1,629,718

187 payments

Through program year 2025, Geisinger Health System is reported as receiving $1,629,718 in research payments, across 187 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $214,835 67
2024 Research $189,032 21
2023 Research $31,974 13
2022 Research $397,442 20
2021 Research $452,223 21
2020 Research $233,614 28
2019 Research $110,597 17

Breakdown

Who paid Research payments · program years 2019–2025
  1. Novo Nordisk Inc $870,313 15 payments
  2. Rhythm Pharmaceuticals, Inc. $398,230 81 payments
  3. Abbott Laboratories $182,805 60 payments
  4. Novocure Inc. $77,860 5 payments
  5. Biogen, Inc. $45,000 1 payment
  6. Novo Nordisk AS $28,158 15 payments
  7. Amgen Inc. $19,040 1 payment
  8. AbbVie, Inc. $8,265 8 payments
  9. Novartis Pharmaceuticals Corporation $47 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. Semaglutide s.c. (Ozempic) and kidney transplant candidacy for patients with stage 4-5 CKD or ESKD $501,708 9 payments
  2. GLP-1 Agonists as Neoadjuvant Therapy for Surgical Treatment of Type 2 Diabetes: An RCT $328,167 5 payments
  3. Long Term Extension Trial of Setmelanotide $260,587 20 payments
  4. Open-Label Extension Study of Setmelanotide in Patients with a Rare Genetic, Syndromic or Acquired Disease of the MC4R Pathway $137,502 60 payments
  5. His Bundle Pacing Pacemaker Mapping Registry $49,668 4 payments
  6. Measuring Disease Outcomes and progression of SMA in the Geisinger Clinic $45,000 1 payment
  7. Geisinger 23866 Still $40,438 1 payment
  8. EF-24 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields) concurrent with standard of care therapies for treatment of stage 4 non-small cell lung cancer (NSCLC) following platinum failure. $36,180 2 payments
  9. EF-27 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150lHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma $23,430 2 payments
  10. LBBAP Data Collection Registry $23,012 4 payments
What the money was spent on Research payments · program years 2019–2025
  1. Patient care $18,560 2 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record